甲氯芬酯治疗轻中度血管性痴呆的临床观察  

Clinical Study of Meclofenoxate Hydrochloride in the Treatment of Vascular Dementia

作　　者：张玉麟[1] 王义方[1] 

机构地区：[1]上海市精神卫生中心

出　　处：《世界临床药物》2007年第1期40-43,共4页World Clinical Drug

摘　　要：目的了解甲氯芬酯治疗轻、中度血管性痴呆(VD)的有效性和安全性。方法30例符合DSM-Ⅳ轻、中度VD诊断标准的患者,一日3次各服甲氯芬酯0.2g,共观察10周。用MMSE、ADL、CGI、GDS、TESS等量表评定疗效和安全性。结果经10周治疗,以MMSE的增分率评定的总有效率为56.7%。CGI评定结果有效率为66.7%。ADL平均减分率虽未达到>25%的有效改善程度,大部分患者日常生活能力均有一定改善。不良反应有2例失眠,2例恶心。结论甲氯芬酯对血管性痴呆有确切疗效,且不良反应较小。Objective To evaluate the clinical efficiency and security of meclofenoxate hydrochloride in the treatment of vascular dementia （VD）. Methods 30 patients who met DSM-IV criteria for VD were treated with meclofenoxate hydrochloride（0.2g tid） for 10 weeks. The MMSE, ADL, CGI, GDS, TESS were used to evaluate of efficiency and security. Result After treatment, The score of MMSE improvement rate was 56.7% and CGI effective rate was 66.7%; ADL scores had declining, though there was no significant difference; and the result show it had no serious adverse reactions. Conclusion Meclofenoxate hydrochloride is effective choice on treatment of VD; the adverse reactions are slight.

关 键 词：氯酯醒 血管性痴呆 不良反应 

分 类 号：R972.4[医药卫生—药品]